Chitosan is a surprising negative modulator of cytotoxic CD8 + T cell responses elicited by adenovirus cancer vaccines

Molecular Pharmaceutics

Volumn 8, Issue 5, 2011, Pages 1652-1661

  Lemke, Caitlin D ^a   Graham, Jessica B ^b   Geary, Sean M ^a   Zamba, Gideon ^a   Lubaroff, David M ^c   Salem, Aliasger K ^a  

^a UNIVERSITY OF IOWA   (United States)

^b University of Iowa   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

adenovirus; cancer vaccine; CD8 + T cell; chitosan; CpG ODN; dendritic cell

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CHITOSAN; GAMMA INTERFERON; OLIGODEOXYNUCLEOTIDE; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CD8+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENE; TUMOR VOLUME; UPREGULATION; ZETA POTENTIAL;

ADENOVIRIDAE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD86; BONE MARROW CELLS; CANCER VACCINES; CELL LINE, TUMOR; CELLS, CULTURED; CHITOSAN; DENDRITIC CELLS; DOWN-REGULATION; GENES, VIRAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA RELEASE TESTS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TRANSGENES;

EID: 80053502259     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100464y     Document Type: Article

References (50)

1. Brossart, P.; Goldrath, A. W.; Butz, E. A.; Martin, S.; Bevan, M. J. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL J. Immunol. 1997, 158 (7) 3270-6 (Pubitemid 127484043)
2. Rosenberg, S. A.; Zhai, Y.; Yang, J. C.; Schwartzentruber, D. J.; Hwu, P.; Marincola, F. M.; Topalian, S. L.; Restifo, N. P.; Seipp, C. A.; Einhorn, J. H.; Roberts, B.; White, D. E. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens J. Natl. Cancer Inst. 1998, 90 (24) 1894-900 (Pubitemid 29014223)
3. Elzey, B. D.; Siemens, D. R.; Ratliff, T. L.; Lubaroff, D. M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors Int. J. Cancer 2001, 94 (6) 842-9 (Pubitemid 33032833)
4. Siemens, D. R.; Elzey, B. D.; Lubaroff, D. M.; Bohlken, C.; Jensen, R. J.; Swanson, A. K.; Ratliff, T. L. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix J. Immunol. 2001, 166 (2) 731-5 (Pubitemid 32060221)
5. Lubaroff, D. M.; Karan, D.; Andrews, M. P.; Acosta, A.; Abouassaly, C.; Sharma, M.; Krieg, A. M. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer Vaccine 2006, 24 (35-36) 6155-62 (Pubitemid 44202567)
6. Karan, D.; Krieg, A. M.; Lubaroff, D. M. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine Int. J. Cancer 2007, 121 (7) 1520-8 (Pubitemid 47328711)
7. Xia, D.; Moyana, T.; Xiang, J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors Cell Res. 2006, 16 (3) 241-59
8. Xie, J.; Xiong, L.; Tao, X.; Li, X.; Su, Y.; Hou, X.; Shi, H. Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin alpha recombinant adenoviral vectors against Lewis lung carcinoma Lung Cancer 2010, 68, 338-345
9. Sorensen, M. R.; Holst, P. J.; Pircher, H.; Christensen, J. P.; Thomsen, A. R. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control Eur. J. Immunol. 2009, 39 (10) 2725-36
10. Lubaroff, D. M.; Konety, B. R.; Link, B.; Gerstbrein, J.; Madsen, T.; Shannon, M.; Howard, J.; Paisley, J.; Boeglin, D.; Ratliff, T. L.; Williams, R. D. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results Clin. Cancer Res. 2009, 15 (23) 7375-80
11. Morelli, A. E.; Larregina, A. T.; Ganster, R. W.; Zahorchak, A. F.; Plowey, J. M.; Takayama, T.; Logar, A. J.; Robbins, P. D.; Falo, L. D.; Thomson, A. W. Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway J. Virol. 2000, 74 (20) 9617-28
12. Miller, G.; Lahrs, S.; Pillarisetty, V. G.; Shah, A. B.; DeMatteo, R. P. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection Cancer Res. 2002, 62 (18) 5260-6 (Pubitemid 35024600)
13. Russell, J. H.; Ley, T. J. Lymphocyte-mediated cytotoxicity Annu. Rev. Immunol. 2002, 20, 323-70 (Pubitemid 34293428)
14. Wagner, H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity Curr. Opin. Microbiol. 2002, 5 (1) 62-9 (Pubitemid 34118159)
15. Rieger, R.; Kipps, T. J. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines Cancer Res. 2003, 63 (14) 4128-35 (Pubitemid 36917937)
16. Tormo, D.; Ferrer, A.; Bosch, P.; Gaffal, E.; Basner-Tschakarjan, E.; Wenzel, J.; Tuting, T. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice Cancer Res. 2006, 66 (10) 5427-35 (Pubitemid 43844970)
17. Salucci, V.; Mennuni, C.; Calvaruso, F.; Cerino, R.; Neuner, P.; Ciliberto, G.; La Monica, N.; Scarselli, E. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand Scand. J. Immunol. 2006, 63 (1) 35-41
18. Lubaroff, D. M.; Karan, D. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer Adv. Drug Delivery Rev. 2009, 61 (3) 268-74
19. Aurisicchio, L.; Peruzzi, D.; Conforti, A.; Dharmapuri, S.; Biondo, A.; Giampaoli, S.; Fridman, A.; Bagchi, A.; Winkelmann, C. T.; Gibson, R.; Kandimalla, E. R.; Agrawal, S.; Ciliberto, G.; La Monica, N. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9 Clin. Cancer Res. 2009, 15 (5) 1575-84
20. Dharmapuri, S.; Peruzzi, D.; Mennuni, C.; Calvaruso, F.; Giampaoli, S.; Barbato, G.; Kandimalla, E. R.; Agrawal, S.; Scarselli, E.; Mesiti, G.; Ciliberto, G.; La Monica, N.; Aurisicchio, L. Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates Mol. Ther. 2009, 17 (10) 1804-13
21. Zaharoff, D. A.; Rogers, C. J.; Hance, K. W.; Schlom, J.; Greiner, J. W. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination Vaccine 2007, 25 (11) 2085-94 (Pubitemid 46227669)
22. Ghendon, Y.; Markushin, S.; Krivtsov, G.; Akopova, I. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines Arch. Virol. 2008, 153 (5) 831-7
23. Ghendon, Y.; Markushin, S.; Vasiliev, Y.; Akopova, I.; Koptiaeva, I.; Krivtsov, G.; Borisova, O.; Ahmatova, N.; Kurbatova, E.; Mazurina, S.; Gervazieva, V. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally J. Med. Virol. 2009, 81 (3) 494-506
24. Saenz, L.; Neira-Carrillo, A.; Paredes, R.; Cortes, M.; Bucarey, S.; Arias, J. L. Chitosan formulations improve the immunogenicity of a GnRH-I peptide-based vaccine Int. J. Pharm. 2009, 369 (1-2) 64-71
25. Slutter, B.; Soema, P. C.; Ding, Z.; Verheul, R.; Hennink, W.; Jiskoot, W. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen J. Controlled Release 2010, 143, 207-214
26. Sui, Z.; Chen, Q.; Wu, R.; Zhang, H.; Zheng, M.; Wang, H.; Chen, Z. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant Arch. Virol. 2010, 155, 535-544
27. Arca, H. C.; Gunbeyaz, M.; Senel, S. Chitosan-based systems for the delivery of vaccine antigens Expert Rev. Vaccines 2009, 8 (7) 937-53
28. Li, H.; Willingham, S. B.; Ting, J. P.; Re, F. Cutting edge: inflammasome activation by alum and alums adjuvant effect are mediated by NLRP3 J. Immunol. 2008, 181 (1) 17-21
29. Borges, O.; Cordeiro-da-Silva, A.; Tavares, J.; Santarem, N.; de Sousa, A.; Borchard, G.; Junginger, H. E. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles Eur. J. Pharm. Biopharm. 2008, 69 (2) 405-16
30. Sayin, B.; Somavarapu, S.; Li, X. W.; Sesardic, D.; Senel, S.; Alpar, O. H. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines Eur. J. Pharm. Sci. 2009, 38 (4) 362-9
31. Hagenaars, N.; Verheul, R. J.; Mooren, I.; de Jong, P. H.; Mastrobattista, E.; Glansbeek, H. L.; Heldens, J. G.; van den Bosch, H.; Hennink, W. E.; Jiskoot, W. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine J. Controlled Release 2009, 140 (2) 126-33
32. Slutter, B.; Plapied, L.; Fievez, V.; Sande, M. A.; des Rieux, A.; Schneider, Y. J.; Van Riet, E.; Jiskoot, W.; Preat, V. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination J. Controlled Release 2009, 138 (2) 113-21
33. Prego, C.; Paolicelli, P.; Diaz, B.; Vicente, S.; Sanchez, A.; Gonzalez-Fernandez, A.; Alonso, M. J. Chitosan-based nanoparticles for improving immunization against hepatitis B infection Vaccine 2010, 28, 2607-2614
34. Marcinkiewicz, J.; Polewska, A.; Knapczyk, J. Immunoadjuvant properties of chitosan Arch. Immunol. Ther. Exp. (Warsz) 1991, 39 (1-2) 127-32
35. Bal, S. M.; Slutter, B.; van Riet, E.; Kruithof, A. C.; Ding, Z.; Kersten, G. F.; Jiskoot, W.; Bouwstra, J. A. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations J. Controlled Release 2010, 142 (3) 374-83
36. Borges, O.; Silva, M.; de Sousa, A.; Borchard, G.; Junginger, H. E.; Cordeiro-da-Silva, A. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen Int. Immunopharmacol. 2008, 8 (13-14) 1773-80
37. Sivakumar, S. M.; Sukumaran, N.; Nirmala, L.; Swarnalakshmi, R.; Anilbabu, B.; Siva, L.; Anbu, J.; Shanmugarajan, T. S.; Ravichandran, V. Immunopotentiation of hepatitis B vaccine using biodegradable polymers as an adjuvant J. Microbiol. Immunol. Infect. 2010, 43 (4) 265-70
38. Chang, H.; Li, X.; Teng, Y.; Liang, Y.; Peng, B.; Fang, F.; Chen, Z. Comparison of adjuvant efficacy of chitosan and aluminum hydroxide for intraperitoneally administered inactivated influenza H5N1 vaccine DNA Cell Biol. 2010, 29 (9) 563-8
39. Sui, Z.; Chen, Q.; Fang, F.; Zheng, M.; Chen, Z. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant Vaccine 2010, 28, 7690-7698
40. Xu, J.; Dai, W.; Wang, Z.; Chen, B.; Li, Z.; Fan, X. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen A (PsaA) protects mice against nasopharyngeal colonization by Streptocoocus pneumoniae Clin. Vaccine Immunol. 2011, 18, 75-81
41. Zaharoff, D. A.; Rogers, C. J.; Hance, K. W.; Schlom, J.; Greiner, J. W. Chitosan solution enhances the immunoadjuvant properties of GM-CSF Vaccine 2007, 25 (52) 8673-86 (Pubitemid 350192060)
42. Heffernan, M. J.; Zaharoff, D. A.; Fallon, J. K.; Schlom, J.; Greiner, J. W. In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines Biomaterials 2011, 32, 926-932
43. Wang, X.; Zhang, X.; Kang, Y.; Jin, H.; Du, X.; Zhao, G.; Yu, Y.; Li, J.; Su, B.; Huang, C.; Wang, B. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus Vaccine 2008, 26 (40) 5135-44
44. Han, H. D.; Song, C. K.; Park, Y. S.; Noh, K. H.; Kim, J. H.; Hwang, T.; Kim, T. W.; Shin, B. C. A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine Int. J. Pharm. 2008, 350 (1-2) 27-34 (Pubitemid 351146677)
45. Seo, S. H.; Han, H. D.; Noh, K. H.; Kim, T. W.; Son, S. W. Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity Clin. Exp. Metastasis 2009, 26 (3) 179-87
46. Intra, J.; Salem, A. K. Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo J. Controlled Release 2008, 130 (2) 129-38
47. Lutz, M. B.; Kukutsch, N.; Ogilvie, A. L.; Rossner, S.; Koch, F.; Romani, N.; Schuler, G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow J. Immunol. Methods 1999, 223 (1) 77-92 (Pubitemid 29096240)
48. Kawamata, Y.; Nagayama, Y.; Nakao, K.; Mizuguchi, H.; Hayakawa, T.; Sato, T.; Ishii, N. Receptor-independent augmentation of adenovirus-mediated gene transfer with chitosan in vitro Biomaterials 2002, 23 (23) 4573-9 (Pubitemid 36151609)
49. Foged, C.; Brodin, B.; Frokjaer, S.; Sundblad, A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model Int. J. Pharm. 2005, 298 (2) 315-22 (Pubitemid 40910735)
50. Mittendorf, E. A.; Sharma, P. Mechanisms of T-cell inhibition: implications for cancer immunotherapy Expert Rev. Vaccines 2010, 9 (1) 89-105